contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


novo-nordisk-has-published-its-annual-report-for-2025

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Novo Nordisk is a producer of insulin for diabetes treatment. In addition to the specialist expertise in diabetes, the company produces drugs for hormone treatment as well as for hemophilia and bleeding disorders. The products are found on a global market and are sold under separate brands. Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark.

Jussi Halme has made a video about Novo Nordisk.  Pharmaceutical giant Novo Nordisk, long known as an unwavering sensation in European stock market history, has drifted into unprecedented turbulence. Until recently, the company’s market value approached 600 billion dollars, but in a short time, more than two-thirds of that value has evaporated. Reasons behind the dramatic share price decline: tightening price pressure in the United States, patent expirations, and the rush of cheap generic drugs into the market. While Novo Nordisk is still churning out billion-dollar profits and has launched a new Wegovy pill, investors are now contemplating whether this is an overreaction or a permanent shift in business dynamics?

Hims & Hers is backing off:                   WKZO | Everything Kalamazoo | 590 AM · 106.9 FM              Hims to stop offering GLP-1 pill after FDA warned of crackdown    By Anusha Shah and Amina Niasse Feb 7 (Reuters) - Online telehealth company Hims & Hers on Saturday reversed course on its launch of a $49 compounded version of Novo Nordisk's Wegovy weight-loss pill after the U.S. Food and Drug Administration said...                             And                   Yahoo Finance              Hims & Hers drops plan for knockoff of Novo Nordisk's new Wegovy weight loss...    Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two days after it announced the new drug and one day after the Food and Drug Administration threatened to restrict access to the...                             Hopefully that rat company Hims & Hers will be brought in line.

There is not something in the water in Denmark,  besides the annoying levels of lime that destroys your household applies  I do also follow Terry Smith’s commentary, and I do agree with him, especially with regard his views of leadership of Novo. What has most surprised me (in a negative way, and I have as of today lost a lot of money because of this) is the failure of Novo leadership to transit from a traditional pharma company operating in a traditional context to an innovative consumer based market, which sometimes resembles a wild west. I do not blame them for their attempts to navigate the Trump chaos, but they have been ’sleeping at the wheel’. In essence, the innovation of Novo with the introduction glp-1 to the market might prove to be the downfall of Novo as we know it. I am quite bearish on Novo going forward. Their pipeline is not impressive and I do Cagrisema will not be able to compensate for the loss of patents and the underlying weakness of Wegovy (ex pills). This might result in acquiring assets at unfavorable prices for the Novo shareholders. My investment thesis of Novo has been wrong. I was naive in trusting that Wegovy would be able to defend some of its market share, both in USA and rest of the world. I thought that since the market is expanding at a rapid pace, there is room for both Novo and Eli. But at the moment, Eli is crushing Novo at all levels. The copycats do not help either. I believe that in the USA Novo is panicking since they changed the Novo USA leadership again. And they hired external people, indicating that there is not proper knowledge within the Novo organization. With regard to the current Novo ceo ambitions to change the internal culture to a more highly competitive one (mimicking Eli) from a nordic ‘hygge’ culture will not work. Culture is in the fabric of the organization and Denmark is the core of it. Most of people working at Novo will not as such care of where the Novo share is trading, especially the scientists who probably sell their shares once they receive any bonus. My point: the Novo organization will still continue to innovate but their organization is steered by a negative narrative that is reactive instead of being pro active. Despite being bearish I have not sold my Novo shares, but I have not added either this year. My target is now 3-5 years in the future and I will continuously be patient by not doing anything. Just sitting on my shares. Because I still do that Glp-1 and the evolution of these will be a cornerstone of how society deals with obesity and soon even Kela will subsidize weigh loss treatments because at the end of the day, not treating obesity has not only personal consequences but is will have tremendous negative effects. I read a Yle article (I cant find it now when I am writing this) that already now overweight/obesity costs the Finnish society 2-3 Billions euros per year. And this number is not going to go down, quite the opposite,  because look at the statistics of the Western world (the rest of the world has similar trajectory), the majority of people are already overweight. And despite of Novo’s shortcomings they do sit of a lot of strengths as well. The production scale is impressive, which the generic production companies will soon find out because most of these lack scale at a level of Novo. They still are the number 2 in this segment and since the cost narrative of glp-1 is following the viagra case, that is the return of investments is coming down quickly, the future players (roche, pfizer, astra etc) will have a hard time getting the return they expected some years ago. — Apologies for the long comment

https://www.cnbc.com/amp/2026/01/09/amazon-pharmacy-starts-offering-novo-nordisks-wegovy-weight-loss-pill.html I see this as good news for both Amazon and Novo, as the Wegovy pill can be sold affordably to the Amazon Prime customer network. This does not bode well for operators like Hims, as Amazon’s logistics and customer network are superior in the USA. Price is certainly under heavy pressure, as monthly injections used to be sold for a thousand euros and now the cheapest pills cost just a few dozen.                   U.S. Food and Drug Administration – 2 Jun 26              FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs    Today, the U.S. Food and Drug Administration is announcing its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies                             The FDA is finally starting to take this “fake” drug problem seriously. ” the U.S. Food and Drug Administration is announcing its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies — including Hims & Hers and other compounding pharmacies — as similar alternatives to FDA-approved drugs. These actions are aimed to safeguard consumers from drugs for which the FDA cannot verify quality, safety, or efficacy.  We take seriously any potential violations of the Federal Food, Drug, and Cosmetic Act. The FDA is also taking steps to combat misleading direct-to-consumer advertising and marketing following warning letters that were sent in the fall of 2025. In promotional materials, companies cannot claim that non-FDA-approved compounded products are generic versions or the same as drugs approved by FDA. They also cannot state compounded drugs use the same active ingredient as the FDA-approved drugs or that compounded drugs are clinically proven to produce results for the patient.”

Thanks for this link! I might not agree with them that much about Novo (US politics has also had a huge impact, and even a large Danish company can’t do anything about that), but the explanations at the beginning of the report regarding how the market has changed with index funds were really interesting.

Terry Smith commented on Novo’s situation in his January investor letter:            fundsmith.co.uk              2025-fef-annual-letter-web.pdf    1297.17 KB                             Novo Nordisk managed to reaffirm my belief that you should never say ‘Things can’t get any worse’. The company has parlayed a market leading position in what is probably the most exciting drug development for about three decades into a secondary position and has failed to prevent illegal generic competition in its core US market. One of our mantras has been that we should always invest in businesses which could be run by an idiot so that performance is not heavily reliant upon management. We have been made painfully aware that the range of businesses which can be run by an idiot is much more limited than we thought and hereafter we will aim to be more aware of the impact that poor management can have. Our experience also suggests that when we encounter poor management, engagement to change it is less effective than selling the shares. Meanwhile Novo Nordisk has appointed a new CEO and made wholesale board changes and the present rating (a PE of 13) appears to us to be expecting very little. If we did not already own it I suspect we would contemplate buying it as a good business which has been depressed by a ‘glitch’, albeit a rather large glitch.  Related to Coloplast, Smith also wrote something only @916 can comment:  Perhaps there is something in the water in Denmark.

Hims & Hers is bringing a drug to market by bypassing the FDA approval process, so they are violating more than just some patent. If such a thing is permitted, why would anyone bother getting the drugs they develop approved by the FDA anymore?

Novo Nordisk

Bagsværd, Denmark, 4 February 2026 – Today, Novo Nordisk A/S has issued its 2025 annual report. The report is available here: https://www.novonordisk.com/investors/annual-report.html and is ...

Bagsværd, Denmark, 4 February 2026 –&nbsp;Today, Novo Nordisk A/S has issued its 2025 annual report. The report is available here: <a href="https://www.globenewswire.com/Tracker?data=fsYKmxUAMhA4qnnZNIeYSUW_SJGnKpGSp5I415DmQ--vUMCh98GCggtzQxMiqeuPhBKE-H__CgYHDAx0jqzOfcGNn58CKUmALh88653EAHytKimiPrIs6zTlD9XB7SVKIOr_X4CQ2yVdQJ3y8qkoQR5OkeC3hzDBAKyaTPUO0xT-r3LPNjm8hyN5ynw54GSiM-qxnTvmVpyrmbVbCMubrAcM2VJGO3PRycTvYj10xf2FySe1lZMkDWSEgMZyCak1tfe9l_TnfSQ067j4eKqO5J5yFA_lsCw77dbFiaZnFUlM-67Atdbph38wp5RP9H4fNBuzXmpKMJ6bWAX9mk0SATCOv-P-ovo9PF8VQqW8mPKup9I7fEmpZbdiZzbL9WHwtFF0lLwjwIX_GVvtnez4P1YBTlnfY1QGySHrr72XFqA=">https://www.novonordisk.com/investors/annual-report.html</a>&nbsp;and is attached in iXBRL format. Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit <a href="https://www.globenewswire.com/Tracker?data=AfBIX_Hk9CtNQll0Dfz8Wxq5kZgORswczV6XFINTh0JCJjJPBMe6JCpE83TEDntbh-Yk4QeNMUDBD82BlsRflF8BxYoc_G0Dyunbb3OqeKM=">novonordisk.com,</a> <a href="https://www.globenewswire.com/Tracker?data=-o5YsEfF-4Vb1e_GEWtHCfAPeh0I3QoLizG4VqF1kCVfnrwRyv112judiLg3LrWGJVFM6n-VBiTlDi0LbhZzjS_kJF3_hRtPC1YayFLyM7Q=">Facebook</a>, <a href="https://www.globenewswire.com/Tracker?data=h3rlcOfJAQvDFPgdhf9-5ucIS7-CVJG2-CLIjy2jwd3SanChVyH-XQff2pRbQv96w9aFIsXQa95nXK1J8dVm6D72tlJjeNVNZKkiIDKuBZI=">Instagram</a>, <a href="https://www.globenewswire.com/Tracker?data=xQwbrI8yv6KTYemMWdT61jSZ5RIef6e6iUpjggHJT9K8FGn1CxFwZCRz1deNGn5gJlIawiEea6-2Na1Sl4JlaA==">X</a>, <a href="https://www.globenewswire.com/Tracker?data=AoKBeS3wkuilpCr4Tq_f2vB8skb0UKolBoZAiqTg-bvnFtAWavteKI4LPxrtX4DQ24Bm0R4FI5-blXwmPDVNryE0oAaU627oShLQkzMC8e_0H6BePuVLJZxG2M7zlXJ4">LinkedIn</a> and <a href="https://www.globenewswire.com/Tracker?data=2BiVy8mrKFhfQbfNfDRp7F6tuUFQmwB-6tvdVzja0B8ivvtI06Bk66e_wNwRw7dY_JI2B9d3EGIGR9s8DzQapw7H0zFOkxeJCIz9LxOUylw=">YouTube</a>. Contacts for further information: <table><tbody><tr><td>Novo Nordisk Media:</td><td>&nbsp;</td></tr><tr><td>Ambre James-Brown +45 3079 9289 <a href="mailto:globalmedia@novonordisk.com,">globalmedia@novonordisk.com</a> </td><td>Liz Skrbkova (US) +1 609 917 0632 <a href="mailto:lzsk@novonordisk.com">lzsk@novonordisk.com</a></td></tr><tr><td>Novo Nordisk Investors:</td><td>&nbsp;</td></tr><tr><td>Michael Novod +45 3075 6050 <a href="mailto:nvno@novonordisk.com">nvno@novonordisk.com</a> </td><td>Jacob Martin Wiborg Rode +45 3075 5956 <a href="mailto:jrde@novonordisk.com">jrde@novonordisk.com</a> </td></tr><tr><td>Sina Meyer +45 3079 6656 <a href="mailto:azey@novonordisk.com">azey@novonordisk.com</a> </td><td>Max Ung +45 3077 6414 <a href="mailto:mxun@novonordisk.com">mxun@novonordisk.com</a> </td></tr><tr><td>Christoffer Sho Togo Tullin +45 3079 1471 <a href="mailto:cftu@novonordisk.com">cftu@novonordisk.com</a> </td><td>Alex Bruce +45 3444 2613 <a href="mailto:axeu@novonordisk.com">axeu@novonordisk.com</a> </td></tr><tr><td>Frederik Taylor Pitter +1 609 613 0568 <a href="mailto:fptr@novonordisk.com">fptr@novonordisk.com</a> </td><td>&nbsp;</td></tr></tbody></table> Company announcement No 5 / 2026 Attachments<ul> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/b3a9153e-1c61-46d4-86c3-18e7aeac204e">NOVO-2025-12-31-1-en</a> </li> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/6e1e992f-facf-4ac3-b68a-08c2fb908b54">CA260204-AR-published</a> </li> </ul><img src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE2MjkwNSM0MDIzMjczMDEjMjAwMjU2MQ==" alt=""> <img src="https://ml-eu.globenewswire.com/media/ZGNmNDIwYzMtZmZhYi00YzdmLTgyMTgtYmQzNTEzM2I2NDExLTEwMTQxMzQtMjAyNi0wMi0wNC1lbg==/tiny/Novo-Nordisk-A-S.png" alt="">

Novo Nordisk Media:
Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com	Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com
Novo Nordisk Investors:
Michael Novod +45 3075 6050 nvno@novonordisk.com	Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com
Sina Meyer +45 3079 6656 azey@novonordisk.com	Max Ung +45 3077 6414 mxun@novonordisk.com
Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com	Alex Bruce +45 3444 2613 axeu@novonordisk.com
Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com